Evgen Pharma
Evgen Pharma plc is a UK clinical-stage drug developer, operating through TheraCryf plc, building proprietary therapeutics for behavioral brain disorders and glioblastoma, targeting opioid/alcohol use, anxiety, fatigue, narcolepsy, and oncology indications through future pharma partnerships.
- Company typePrivate
- Founded2007
- HeadquartersWilmslow, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Evgen Pharma does
Evgen Pharma plc (LSE: EVG) is a UK-based, clinical-stage drug development company founded in 2007 and headquartered in Wilmslow, operating primarily through its subsidiary TheraCryf plc. The company's stated focus is developing novel therapeutics for cancer (glioblastoma) and neurological/behavioral brain disorders, with three lead programs in its pipeline: Ox-1, a candidate-stage orexin-1 receptor antagonist aimed at substance use disorders (opioid/alcohol abuse) and anxiety, designed to overcome side effects limiting other orexin-1 blockers; DAT, an atypical inhibitor of the brain dopamine transporter positioned for central fatigue and narcolepsy; and SFX-01, a pre-clinical asset showing tumor shrinkage and extended survival in glioblastoma models, advanced in collaboration with Erasmus Medical Centre Rotterdam on a fully grant-funded basis.
The commercial strategy is to generate proof-of-concept data sets in carefully selected indications and then partner each program with mid-size to large pharma for later-stage trials and commercialization, rather than build internal commercial infrastructure. The business model at present is capital-intensive and pre-revenue: revenue would derive from partnership milestones, royalties, and ultimately pharmaceutical distribution following regulatory approval. There is no disclosed product pricing, customer list, or distribution channel; market reach is theoretical through a stated addressable population of more than 50 million people affected by behavioral brain disorders globally. In March 2024 Evgen announced an all-share acquisition of Chronos Therapeutics Ltd. for up to £3.4 million to broaden the CNS pipeline.
Operational scale is small — firmographic data lists 1–10 employees — consistent with a lean virtual/biotech model that relies on academic collaborators (Erasmus MC), grant funding, and outsourced clinical work. Cumulative disclosed funding since 2009 amounts to roughly $16.4 million across rounds led or participated in by The North West Fund, Imprimatur Capital, Enterprise Ventures, Sarum Partners, Seneca Partners, and Acceleris Capital, with the largest round ($13.65M) closed in February 2021. The company is led by Chairman Barry Clare and supported by a Scientific Advisory Board; specific senior management detail is limited in the provided inputs.
Evgen Pharma firmographics
Firmographics- Name
- Evgen Pharma
- Legal name
- TheraCryf plc
- Website
- https://evgen.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Evgen Pharma plc is a UK clinical-stage drug developer, operating through TheraCryf plc, building proprietary therapeutics for behavioral brain disorders and glioblastoma, targeting opioid/alcohol use, anxiety, fatigue, narcolepsy, and oncology indications through future pharma partnerships.
- Ownership category
- akta.pro rank
Evgen Pharma industry classification
Industry- Product category
- Clinical-stage biopharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
- akta.pro secondary industries
- Specialty Care Pharmaceuticals (HLAIAAAB), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where Evgen Pharma is headquartered
LocationHeadquarters
- HQ city
- Wilmslow
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Evgen Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Evgen Pharma product offering
Product offeringCore offering
Evgen Pharma (legal name TheraCryf plc) is a clinical-stage drug development company developing proprietary therapeutic candidates targeting behavioural brain disorders and glioblastoma. Its pipeline includes Ox-1 (an orexin-1 receptor antagonist) for substance use disorders and anxiety, DAT (a dopamine transporter inhibitor) for fatigue and narcolepsy, and SFX-01 for glioblastoma treatment. The company partners with mid-size to large pharmaceutical companies to advance these candidates through clinical development.
Product overview
Evgen Pharma is a clinical stage therapeutics company focused on developing innovative pharmaceuticals. Based on the available source data, the company is involved in the acquisition and development of therapeutic candidates, including the planned acquisition of Chronos Therapeutics Ltd. and operations through its subsidiary TheraCryf plc, which develops treatments for behavioural brain disorders such as substance use disorders, anxiety, fatigue, narcolepsy, and glioblastoma.
Differentiator
Problem solved
Functional benefit
Products and services
- Ox-1
- DAT (Dopamine Transporter Inhibitor)
- SFX-01
Quantifiable outcome
- Pre-clinical models show positive data for SFX-01 on tumour shrinkage and extended survival times
Companies that use Evgen Pharma
Customer profileSegments1 record
Ideal customer profiles1 record
Evgen Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Evgen Pharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Erasmus Medical Centre RotterdamcoreTheraCryf is working in collaboration with Erasmus Medical Centre Rotterdam, NL on a fully grant funded programme to bring SFX-01 to patients with glioblastoma.
Recent moves5 records
Expansion highlights5 records
Evgen Pharma competitors and assessment
Company assessmentDirect peers
- Intra-Cellular Therapies: US clinical-stage then commercial CNS developer focused on neuropsychiatry. Comparable in being a CNS-pure-play that progressed from clinical stage to approval via differentiated mechanism work — a relevant template for TheraCryf's partnership-led strategy.
- Tonix Pharmaceuticals: US clinical-stage CNS-focused biotech working across psychiatry and neurology. Comparable as a small-cap, CNS-pure-play developer pursuing multiple indications with limited headcount.
- Axsome Therapeutics: US clinical-stage then commercial CNS developer focused on neuropsychiatry indications including anxiety and binge eating. Closely comparable to TheraCryf's Ox-1 indication mix and partnership-led progression model.
- Avadel Pharmaceuticals: Ireland/US specialty pharma with an approved narcolepsy therapy (FT218). Comparable on the narcolepsy indication TheraCryf's DAT programme targets, and on the small-cap CNS specialty business model.
- Sosei Heptares: Japan- and UK-based clinical-stage GPCR-focused drug developer with active orexin receptor programmes. Directly comparable to TheraCryf on the Ox-1 mechanism and CNS pipeline focus, though operating at significantly larger scale.
- NLS Pharmaceutics: Swiss clinical-stage CNS developer with assets targeting narcolepsy and related sleep/CNS disorders. Directly comparable to TheraCryf's DAT programme positioning in narcolepsy and central fatigue.
- Minerva Neurosciences: US clinical-stage CNS biotech with a small pipeline in neuropsychiatry. Closely comparable in scale, stage and CNS-only focus, and useful as a peer for capital markets sentiment around small-cap CNS assets.
- Idorsia Pharmaceuticals: Swiss clinical-stage CNS specialty pharma focused on neurology and psychiatry. Closely comparable business model (clinical-stage CNS innovator pursuing partnership/out-license economics) and indication mix.
Broad incumbents
- Jazz Pharmaceuticals: Established CNS/neurology specialty pharma with leading narcolepsy franchises (Xywav, Xyrem). Comparable as the dominant commercial player in narcolepsy that any small CNS developer targeting that indication must be benchmarked against.
- Takeda Pharmaceutical: Global pharma with established orexin receptor programmes (Dayvigo) in sleep/CNS. Comparable as the large-pharma counterparty TheraCryf explicitly wants to partner with and as the benchmark for what scale orexin commercialisation looks like.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Evgen Pharma social profiles
Digital presenceEvgen Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Evgen Pharma leadership team
Management profileNumber of profiles
Profiles1 record
Evgen Pharma funding detail
Funding detailFunding overview
Funding rounds5 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Evgen Pharma M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Evgen Pharma
What does Evgen Pharma do?
Evgen Pharma (legal name TheraCryf plc) is a clinical-stage drug development company developing proprietary therapeutic candidates targeting behavioural brain disorders and glioblastoma. Its pipeline includes Ox-1 (an orexin-1 receptor antagonist) for substance use disorders and anxiety, DAT (a dopamine transporter inhibitor) for fatigue and narcolepsy, and SFX-01 for glioblastoma treatment. The company partners with mid-size to large pharmaceutical companies to advance these candidates through clinical development.
Is Evgen Pharma a public or private company?
Evgen Pharma is a private company. It is classified as public and is currently operating.
When was Evgen Pharma founded?
Evgen Pharma was founded in 2007. It employs 1 to 10 people.
Where is Evgen Pharma based?
Evgen Pharma is headquartered in Wilmslow, United Kingdom, in the Europe region.
Who are Evgen Pharma's main competitors?
Direct peers on record are Intra-Cellular Therapies, Tonix Pharmaceuticals, Axsome Therapeutics, Avadel Pharmaceuticals, Sosei Heptares, NLS Pharmaceutics, Minerva Neurosciences and Idorsia Pharmaceuticals. Broad incumbents are Jazz Pharmaceuticals and Takeda Pharmaceutical.
Does Evgen Pharma have an API?
No public API is recorded for Evgen Pharma.
What industry is Evgen Pharma in?
Evgen Pharma's product category is Clinical-stage biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.